Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
CONCLUSIONS: Compared with zoledronic acid, denosumab provides a cost-effective treatment option for the prevention of SREs in patients with prostate cancer, breast cancer, and OST in the Czech Republic.
PMID: 28485692 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Czechia Health | Economics | Health Management | Prostate Cancer | Reclast | Study | Xgeva | Zometa